Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 121.64B +88.0% |
| Revenue (ttm) | 54.78B +4.4% |
| Net Income | 4.94B |
| EPS | 4.23 |
| Shares Out | n/a |
| PE Ratio | 24.62 |
| Forward PE | 14.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 743,432 |
| Average Volume | 1,526,321 |
| Open | 10,360 |
| Previous Close | 10,250 |
| Day's Range | 10,340 - 10,520 |
| 52-Week Range | 5,305 - 11,350 |
| Beta | 0.86 |
| RSI | 60.38 |
| Earnings Date | Apr 29, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Insider Sell: Amir Weiss Sells Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Insider Sell: Amir Weiss Sells Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Teva price target raised to $40 from $38 at Barclays
Barclays raised the firm’s price target on Teva (TEVA) to $40 from $38 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for
Royalty Pharma Reports Q1 2026 Results: Full Earnings Call Transcript
Royalty Pharma (NASDAQ: RPRX) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For rea...
Insider Sell Alert: Mark Sabag Sells 144,180 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Insider Sell Alert: Mark Sabag Sells 144,180 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Teva to Present at the BofA Securities Health Care Conference
PARSIPPANY, N.J., and TEL AVIV, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Me...
TEVA Maintained by JP Morgan -- Price Target Raised to $40.00
TEVA Maintained by JP Morgan -- Price Target Raised to $40.00
TEVA Maintained by UBS -- Price Target Raised to $42.00
TEVA Maintained by UBS -- Price Target Raised to $42.00
TEVA Reiterated by Piper Sandler -- Price Target Raised to $42.00
TEVA Reiterated by Piper Sandler -- Price Target Raised to $42.00
TEVA Maintains Buy Rating with Truist Securities -- Price Target Raised to $45
TEVA Maintains Buy Rating with Truist Securities -- Price Target Raised to $45
Teva price target raised to $50 from $45 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Teva (TEVA) to $50 from $45 and keeps a Buy rating on the shares. Teva delivered encouraging results, with strong outperformance in
Teva price target raised to $40 from $35 at JPMorgan
JPMorgan raised the firm’s price target on Teva (TEVA) to $40 from $35 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for
Teva price target raised to $42 from $41 at Piper Sandler
Piper Sandler raised the firm’s price target on Teva (TEVA) to $42 from $41 and keeps an Overweight rating on the shares following quarterly results. The firm notes Teva continues
Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
TEL AVIV, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2025 Healthy Future Report, outlining performance against its sustain...
Teva price target raised to $42 from $36 at UBS
UBS raised the firm’s price target on Teva (TEVA) to $42 from $36 and keeps a Buy rating on the shares. Teva reported Q1 results that reinforce improving confidence in
Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?
A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2026 Earnings Call Highlights: Strong Innovative ...
Teva Pharmaceutical Industries Ltd (TEVA) Q1 2026 Earnings Call Highlights: Strong Innovative Portfolio Growth Amid Revenue Challenges
Q1 2026 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Q1 2026 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Teva Pharmaceutical Industries Ltd (TEVA) Shares Surge 11.9% -- What GF Score of 58 Tells Investors
Teva Pharmaceutical Industries Ltd (TEVA) Shares Surge 11.9% -- What GF Score of 58 Tells Investors
Teva price target raised to $45 from $42 at Truist
Truist raised the firm’s price target on Teva (TEVA) to $45 from $42 and keeps a Buy rating on the shares after announcing “strong” Q1 results, and the acquisition of
Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio
Teva Pharmaceuticals CEO Richard Francis joins 'Money Movers' to discuss the company's latest acquisition of Emalex Biosciences, their latest drug offerings, and more.
Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), on Wednesday agreed to acquire Emalex Biosciences, including its lead asset, ecopipam.
Unusually active option classes on open April 29th
Unusual total active option classes on open include: Intellia Therapeutics (NTLA), Teva (TEVA), FuelCell (FCEL), iShares 20 Year Treasury Bond ETF (TLT), BigBearai Holdings (BBAI), Qualcomm (QCOM), Jo...
TEVA Forecasts Steady Revenue Growth and Strong Margins
TEVA Forecasts Steady Revenue Growth and Strong Margins
TEVA Expects Positive Impact from Emalex Acquisition
TEVA Expects Positive Impact from Emalex Acquisition
TEVA Forecasts $700 Million in Savings by 2027
TEVA Forecasts $700 Million in Savings by 2027